Home > Boards > US Listed > Biotechs > Calithera Biosciences, Inc. (CALA)

Bristol-Myers and Calithera expand clinical collaboration

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
nlightn Member Profile
 
Followed By 137
Posts 42,398
Boards Moderated 7
Alias Born 01/05/04
160x600 placeholder
Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced ... GlobeNewswire Inc. - 10/3/2019 7:05:00 AM
Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annua... GlobeNewswire Inc. - 10/1/2019 4:05:00 PM
New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab GlobeNewswire Inc. - 9/29/2019 10:30:00 AM
Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Re... GlobeNewswire Inc. - 9/28/2019 2:30:00 AM
Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Cong... GlobeNewswire Inc. - 9/26/2019 6:05:00 PM
Calithera to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/25/2019 8:05:00 AM
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019 GlobeNewswire Inc. - 9/3/2019 9:00:00 AM
Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference GlobeNewswire Inc. - 8/28/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/8/2019 4:18:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/8/2019 4:07:23 PM
Calithera Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights GlobeNewswire Inc. - 8/8/2019 4:05:00 PM
Calithera Biosciences to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019 GlobeNewswire Inc. - 8/1/2019 7:07:00 AM
Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with Pfizer’s CDK4/6 Inhibitor Palbociclib GlobeNewswire Inc. - 7/2/2019 8:00:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/1/2019 4:08:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/27/2019 4:08:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/27/2019 4:07:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/26/2019 4:06:38 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 6/25/2019 4:50:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/21/2019 4:06:46 PM
Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares... GlobeNewswire Inc. - 6/21/2019 4:04:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2019 4:55:19 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/19/2019 4:51:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/19/2019 4:07:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/19/2019 4:06:00 PM
Calithera Biosciences, Inc. Prices Public Offering of 12,500,000 shares of Common Stock GlobeNewswire Inc. - 6/18/2019 11:00:00 PM
nlightn   Monday, 05/15/17 07:07:11 AM
Re: None
Post # of 193 
Bristol-Myers and Calithera expand clinical collaboration

May 15, 2017 6:56 AM ET

Bristol-Myers Squibb (NYSE:BMY) and Calithera Biosciences (NASDAQ:CALA) expand their cancer collaboration assessing Opdivo (nivolumab) and CB-839. They plan to evaluate the combination in non-small cell lung cancer (NSCLC) and melanoma. A clinical trial in clear cell renal cell carcinoma is already underway.

CB-839 is an orally administered inhibitor of an enzyme called glutaminase. It is designed to starve tumor cells of a protein called glutamine, a key nutrient. The rationale is that it may enhance the effects of checkpoint inhibitors and may reverse tumor resistance to checkpoint inhibitors by altering the immune-suppressive microenvironment and promoting an anti-tumor immune response. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression.

invest at your own risk, based on your own due diligence, at your own risk tolerance

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist